17 completed, 1 active not recruiting. 8 Phase 2, 7 Phase 3, 4 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Active not recruiting 1 |
| Phase 3 | 7 | Completed 7 |
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Prevnar 13®: new trials by email Literature Review of Prevnar 13® trials Research Report on Prevnar 13®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine - Meningococcal Immunization, Healthy Volunteers | Phase 1 / Phase 2 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 750 | 2024-11-05 | 2026-01-20 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV) - Meningococcal Immunisation, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1528 | 2023-03-27 | 2026-01-21 |
| Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3 - Pneumococcal Immunisation, Diphtheria Immunisation | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 852 | 2020-05-22 | 2025-09-08 |
| Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) V114, Prevnar 13® - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 606 | 2019-06-25 | 2023-01-13 |
| Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) V114, Prevnar 13® - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1205 | 2019-06-13 | 2021-04-26 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) V114, Pneumococcal 13-valent Conjugate Vaccine (PCV13), Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV) - Pneumococcal Infections | Phase 1 | Completed | Merck Sharp & Dohme LLC | 133 | 2019-04-02 | 2025-01-15 |
| Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years) Pneumococcal Conjugate Vaccine, Prevnar 13® - Pneumococcal Immunization | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 175 | 2018-12-03 | 2024-11-20 |
| Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 525 | 2018-10-17 | 2023-10-19 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2627 | 2018-04-25 | 2024-10-15 |
| Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) V114-A, V114-B, Prevnar 13® - Pneumococcal Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 690 | 2015-10-08 | 2019-04-16 |
| A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays Menveo®, Boostrix®, Pneumovax 23® - Meningococcal | Phase 4 | Completed | GlaxoSmithKline | 359 | 2014-04-01 | 2017-11-27 |
| Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix® - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 600 | 2014-02-01 | 2018-09-14 |
| Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) Prevnar 13®, V114 1x:1x:1x, V114 2x:2x:2x - Streptococcus Pneumoniae Infection, Pneumococcal Infections | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 341 | 2014-01-28 | 2019-06-24 |
| An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13) - Rheumatoid Arthritis | Phase 2 | Completed | AbbVie | 493 | 2014-01-24 | 2022-07-12 |
| Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13® - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 1806 | 2012-05-21 | 2019-12-27 |
| Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) V419, PREVNAR 13®, MCC-TT - Neisseria Meningitidis, Bacterial Infections | Phase 3 | Completed | MCM Vaccines B.V. | 284 | 2012-03-30 | 2019-03-28 |
| The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) Pneumococcal Conjugate Vaccine (V114), PNEUMOVAX® 23, PREVNAR 13® - Pneumococcal Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 692 | 2012-03-13 | 2018-12-13 |
| A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003) V114 Aluminum-adjuvanted, V114 Non-adjuvanted, Prevnar 13® - Pneumococcal Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1152 | 2010-10-14 | 2019-04-30 |
Pneumococcal Infections (7) · Meningococcal Infections (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Bacterial Infections (1) · Diphtheria (1) · Haemophilus Infections (1) · Joint Diseases (1) · Meningitis, Meningococcal (1) · Musculoskeletal Diseases (1) · Pneumonia (1) · Streptococcal Infections (1) · Tetanus (1) · Virus Diseases (1) · Whooping Cough (1)
Merck Sharp & Dohme LLC (7) · Sanofi Pasteur, a Sanofi Company (6) · GlaxoSmithKline (3) · AbbVie (1) · MCM Vaccines B.V. (1)
United States (7) · Canada (3) · Poland (3) · Puerto Rico (3) · Russia (3) · Spain (3) · Czechia (2) · Finland (2) · Honduras (2) · Japan (2) · Mexico (2) · South Africa (2) · United Kingdom (2) · Belgium (1) · Brazil (1)
PMID 29559167, PMID 30244873, PMID 30648919, PMID 30689507, PMID 34507861, PMID 35246470, PMID 36150974, PMID 36882898, PMID 37199884, PMID 37723577, PMID 39384037, PMID 41337697, PMID 41489614
2018 (3), 2023 (1)